Alcon's Latest Breakthrough Surgical Technology, Unity VCS, receives Health Canada approval
Combined vitreoretinal-cataract system (VCS) is cleared for use in Canada
New, proprietary technology is designed to deliver significant surgical and workflow efficiencies
First innovation to be introduced from Alcon's cutting-edge Unity portfolio of surgical equipment
Article content
TORONTO — Alcon, the global leader in eye care dedicated to helping people see brilliantly, today announced that UNITY ® Vitreoretinal Cataract System (VCS) has received Health Canada approval. This innovation is the first to be introduced from Alcon's highly anticipated Unity portfolio.
Article content
'This is a proud moment to see the world-class innovation from Alcon receive approval in Canada,' said Dr. Rosa Braga-Mele, ophthalmologist and chair of Alcon's North America Cataract Core Advisory Board.
'Today marks an important day for Canadian ophthalmologists as we introduce the next generation of equipment solutions in cataract and vitreoretinal surgery, and we are grateful to those who helped us reach this milestone,' said Franck Leveiller, Head of Global R&D and Chief Scientific Officer, Alcon. 'We have a long legacy of engaging our customers throughout the research and development process to design bold innovations in ophthalmology. This approval is a significant milestone in delivering meaningful impact for Canadian Eye Care Professionals and patients.'
Article content
Unity VCS is Alcon's most advanced vitreoretinal and cataract surgical innovations combined together in one integrated platform. Unity VCS is designed to deliver enhanced workflow efficiencies over Alcon's current leading systems, CONSTELLATION ® Vision System for vitreoretinal and combined procedures, and CENTURION ® Vision System with ACTIVE SENTRY ® for cataract surgery.
Article content
'The first time I used Unity VCS in a wet lab environment, I had a real 'wow' reaction,' said Dr. Rosa Braga-Mele, ophthalmologist and chair of Alcon's North America Cataract Core Advisory Board. 'This is a proud moment to see the world-class innovation from Alcon receive approval in Canada. I'm particularly excited about the stability of the fluidics and cutting efficiency of the platform, which is quite remarkable and will create considerable surgical efficiencies.'
Article content
Unity VCS leverages a novel phacoemulsification modality to deliver up to two times faster nucleus removal ^ with 40% less energy * into the eye 1, and a first-of-its-kind phaco handpiece that estimates temperature at the incision site 3. In vitreoretinal advancements, the new technology offers cutting speeds of up to 30,000 cuts per minute, the world's fastest vitrectomy probe #,2,3. The platform offers surgical stability and efficiency with a unique proprietary fluidics system 3.
Article content
'As a global market leader in cataract and retina surgical products 4,5,6, Alcon recognizes that the increasing demand for these procedures 7,8,9 necessitates enhanced workflow efficiencies and excellent patient outcomes,' said Jeroen Bastemeijer, General Manager, Alcon Canada. 'Unity VCS builds on Alcon's expertise in surgical equipment with pioneering innovations for vitreoretinal and cataract surgery—driving advancements from cutting speeds to fluidics management, to ergonomics and workflow. We are thrilled to bring this latest breakthrough technology, Unity VCS, to Canadian clinics in 2026.'
Article content
Alcon has tested Unity VCS during investigational advisory wet lab sessions with more than 200 highly experienced surgeons from 30+ countries. Commercial launch of Unity VCS is expected in early 2026.
Article content
Unity VCS is the latest innovation from the Alcon Vision Suite—a portfolio of innovative products designed to help Eye Care Professionals increase clinic and OR efficiency, and deliver exceptional patient experiences. The Alcon Vision Suite will continue to grow with cutting-edge Unity products that are expected to be introduced over the coming years, adding to our market-leading legacy products, which will continue to be available and serviceable. Unity VCS will be supported by Alcon's training, product maintenance, and Services teams.
Article content
About Alcon
Article content
Alcon helps people see brilliantly. As the global leader in eye care with a heritage spanning over 75 years, we offer the broadest portfolio of products to enhance sight and improve people's lives. Our Surgical and Vision Care products touch the lives of more than 260 million people in over 140 countries each year living with conditions like cataracts, glaucoma, retinal diseases and refractive errors. Our more than 25,000 associates are enhancing the quality of life through innovative products, partnerships with Eye Care Professionals and programs that advance access to quality eye care. Learn more at
Article content
.
Article content
Indications / Intended Use 3:
Article content
The
Article content
UNITY ® VCS
Article content
(Vitreoretinal Cataract System) console, when used with compatible devices, is indicated for use during anterior segment (i.e. phacoemulsification and removal of cataracts) and posterior segment (i.e. vitreoretinal) ophthalmic surgery. In addition, with the optional laser, this system is indicated for photocoagulation (i.e. vitreoretinal and macular pathologies), iridotomy and trabeculoplasty procedures.
Article content
Please refer to the Directions for Use for the accessories/consumables and User Manual for a complete listing of indications, warnings, cautions and notes.
Article content
^2x faster nucleus removal than OZIL Torsional phaco
*Based on N=10 HPs, Artificial cataract lens IOP 55 mmHg vacuum of 450 mmHg
# Compared to Constellation HYPERVIT 20k vitrectomy probe
OZIL – Trademarks are the property of their respective owners. References
Alcon Data on File, 2024 – REF-24379.
Alcon Data on File, 2024 – REF-24644.
Unity VCS User Manual 2024 – REF-24980.
Market Scope 2023 Retinal Surgical Device Market Report, 2023.
Market Scope 2023 Cataract Surgical Equipment Market Report, 2023.
Market Scope 2024 IOL Market Report, 2024.
CNIB – Blindness in Canada, Accessed December 2, 2024 – REF-19527.
The Prevalence of Canadian Vision Loss and Cataract Surgery, 2019 – REF-01661.
Conference Board of Canada – Ophthalmology in Canada: Why Vision Loss Should Not Be Overlooked, 2020 – REF-10834.
Connect with us on
Article content
Article content
Article content
Article content
Contacts
Article content
Media Relations
Article content
Article content
Jane Lee Cheung
Article content
Article content
Article content
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
26 minutes ago
The U.S. economy is thriving in spite of tariffs. Will it last?
By just about every indicator, the U.S. economy is holding up remarkably well. When Donald Trump launched his global trade war, economists and markets said his tariff policy would slow the economy, drive up prices and dramatically reduce global trade. And yet, stocks are at all-time highs, the country's employment is strong, its economy is expanding and the expected surge in inflation hasn't materialized. Canada's economy has shown surprising resilience, as well, with consumer spending starting to pick up last month and unemployment declining. Economists told CBC News it's unclear whether the tariffs' impact was overestimated, or if further pain lies ahead. But they say resilience in both countries is fragile, and could be quickly upended if the trade war worsens or expands. A lack of retaliation BMO's chief economist Douglas Porter says two key factors are driving the recent U.S. resilience. Other nations have not really been retaliating against the U.S., so their own exports are not facing that much pressure. And on the flip side, the U.S. consumer has been pretty heavily sheltered so far from this, said Porter. In the meantime, American businesses have not passed on the costs of tariffs. General Motors, for example, released earnings last week that said Trump's tariff policies drove down profits by 35 per cent in the second quarter. The automaker said tariffs on cars and parts led to a $1.1-billion US loss in its quarterly earnings. But still, it has not increased prices. Enlarge image (new window) GM said its profits fell by $1.1 billion US in the second quarter of this year as a result of Trump's tariffs. Photo: Reuters / Chris Helgren Royce Mendes, managing director at Desjardins Capital Markets, says that's becoming a trend among affected American companies. Some companies may choose to just eat the tariff increase in costs rather than draw the ire of President Trump, said Mendes. GM stock fell on the news, but has since rebounded, paring losses and climbing almost all the way back to where it was before it published its earnings. Financial markets have had some pretty volatile sessions, including steep sell-offs when tariffs are announced, and big rallies when exemptions are made. But stock markets in both Canada and the U.S. are at or near record highs — which investors believe is a sign that the resilience we're seeing will last. A stockpile of products The question, though, is whether the impact of the tariffs has simply been delayed. When the levies were first announced last spring, businesses around the world scrambled to get product out the door and into the United States. That has led to a huge stockpile of products — and it means American importers have not yet had to bear the worst of the tariffs. WATCH | The future of Canada-U.S. free trade: There was a lot of front-running and that may be one of the big reasons why we haven't seen much impact yet, said BMO's Porter. There's probably some pain to come, but I don't think it's going to be as bad as many economists were fretting about earlier this year, at least for the U.S. Canada's economy has shown resilience, too But both economists point to the fact that Canada's economy has also fared better than almost anyone had expected. Economic growth shrank in April, but only by 0.1 per cent. Statistics Canada says another 0.1 per cent decline is likely for May. (Those numbers will be confirmed on Thursday.) The unemployment rate has actually begun to decline since peaking in May at seven per cent. And last week's retail sales figures showed consumer spending had started to pick up again in June. We've been pointing to this broader resilience in consumer spending, said Claire Fan, a senior economist with RBC. She says consumer sentiment plunged in the spring, at the height of the uncertainty. But since then, RBC crunched U.S. customs data and found exemptions for CUSMA-compliant products (new window) have dragged the average effective tariff rate all the way down to as low as 2.3 per cent. It's a reflection of President Trump's overall strategy of coming out very aggressive early on, but then walking things back. I mean, the tariffs have not been as punitive for Canada as initially believed — nowhere close to it, said Mendes of Desjardins. Sector-specific pain However, real damage has been done in sectors like auto, steel, aluminum and lumber. The concern now is that the carve-outs Canada has secured for CUSMA-compliant products won't last. Unless a trade deal is reached to significantly reduce U.S.-Canada tariffs by Aug. 1, when new U.S. tariffs are set to come into effect, we expect job losses and higher prices from tariffs to squeeze disposable income and cause households to tighten their purse strings, wrote Michael Davenport, senior economist at Oxford Economics in a note to clients. WATCH | Negotiations continue between Canada and the U.S.: On the one hand, some in the Trump administration will look at the U.S. economy's relative resilience as a reason to double down and push harder for more and more punitive tariffs. But escalation wouldn't just be bad for the Canadian economy. Right now, most businesses and consumers on both sides of the border have been sheltered from the worst impacts of the tariffs. That shelter depends on a fine and tricky balance of importers eating some costs, exporters dropping some prices and countries limiting retaliatory measures. Upending that balance further comes with risks on both sides of the dispute. Peter Armstrong (new window) · CBC News · Senior Business Reporter Peter Armstrong is a senior business reporter for CBC News. A former host of On the Money and World Report on CBC Radio, he was previously a foreign correspondent and parliamentary reporter for CBC. Subscribe to Peter's newsletter here: Twitter: @armstrongcbc
CTV News
26 minutes ago
- CTV News
York police charge doctor with two counts of sexual assault
Police in York Region have arrested a doctor on sexual assault charges. York's Criminal Investigations Bureau have charged a doctor with sexual assault after a victim reported two incidences. Police say the person attended a medical clinic on Markham Road. During the visit, the person said the doctor touched them in a sexual manner. The victim left immediately and reported the incident to the police. While telling police of the experience, the person also recalled a previous appointment at the same clinic in November 2023, when the doctor's actions were also inappropriate. At that time, the person didn't report the event because they believed the conduct might have been part of a legitimate medical procedure. Police are asking the public to review the photo of Dr. Saber Abdel Malouka Abdel Malak, 62, of Whitchurch-Stouffville who has been a physician for more than 30 years. Police say a sexual assault includes any non-consensual contact of a sexual nature. They encourage anyone who feels they may have been a victim to report the incident to the police. To make an online report click here. Anyone with information is asked to call the York Regional Police Special Victims Unit at 1-866-876-5423, ext. 7071. Anonymous tips can be made by calling Crime Stoppers at 1-800-222-TIPS.
National Post
26 minutes ago
- National Post
Pluristyx Completes Investment Round to Expand Product Portfolio and Commercial Operations
Article content SEATTLE — Pluristyx, a leading provider of induced pluripotent stem cell (iPSC) technologies and proprietary gene editing solutions, today announced the successful close of its most recent round of funding led by BioLife Solutions, the global leader in cryopreservation technologies and systems that support cell and gene therapy (CGT) manufacturing, and BroadOak Capital Partners, a specialist investor in the life science tools and services industry. Article content The newly raised capital will enable Pluristyx to expand inventory with new clinical grade cell lines incorporating Pluristyx's proprietary FailSafe® and iACT™ engineering and hypoimmune genetic edits in its best-in-class, polyclonal, synthetic RNA reprogramed iPSCs. These proprietary cells are specifically designed to support making next-generation genetically engineered, stem cell-derived therapies and support uniquely safe, effective, and scalable living medicines. The funding will also support Pluristyx's recently launched PluriForm ™ kit, which provides researchers with streamlined tools for generating organoids and other complex test systems. Article content 'We are incredibly excited for the successful close of this round and gratified to have industry leaders and peers validate our vision with their investment,' said Benjamin Fryer, PhD, CEO of Pluristyx. 'The support from our Seattle area neighbor, BioLife Solutions, and continued support from our colleagues at BroadOak Partners will allow us to manufacture, commercialize, and distribute our innovative solutions and help our customers solve critical industry challenges.' Article content Roderick de Greef, BioLife's Chairman and CEO, remarked, 'We have known and worked with the founding team at Pluristyx for many years, and have a great deal of respect for their scientific expertise in cell therapy. Their recent development of an iPSC-based biological assay for organoid manufacturing dovetails with our interest in exploring biological assays more broadly as a product portfolio adjacency.' Article content 'We are excited to continue our support of Dr. Fryer and the entire Pluristyx team,' said Daniel Friedman, Principal at BroadOak Capital Partners. 'Pluristyx is differentiated by its suite of proprietary technologies that directly address some of the most critical scientific challenges of the iPSC field.' Article content iPSCs are unique tools and building blocks for medicines. In addition to applications for innovative new toxicology, safety, and efficacy assays to replace animal models, Pluristyx's products are the ideal universal raw material to produce living medicines to cure currently untreatable diseases. This strategic investment will enable Pluristyx to be the industry leader offering the highest quality stem cells available anywhere. Article content About BioLife Solutions Article content BioLife Solutions is a leading developer and supplier of bioproduction products and services for the cell and gene therapy (CGT) and broader biopharma markets. Our expertise facilitates the commercialization of new therapies by supplying solutions that maintain the health and function of biologic materials during collection, development, storage, and distribution. For more information, please visit or follow BioLife on LinkedIn and X. Article content About BroadOak Capital Partners Article content BroadOak Capital Partners is a boutique financial institution that provides direct investment and investment banking services to companies in the life science tools, diagnostics, and biopharma services sectors. BroadOak has led or participated in investments in over 70 companies across the life sciences industry. For more information, visit Article content Pluristyx is dedicated to enabling the development of next-generation cell-based tools and therapies. PluriKit™, PluriForm™ Organoids, and PluriBank™ stem cells incorporating safety and tolerance features like FailSafe®, iACT™, and hypoimmune engineering streamline developers' path to the clinic and approval. Pluristyx's iPSC lines, backed by an FDA registered drug master file, with platform genetic engineering are available 'off-the-shelf' along with comprehensive support services to accelerate the creation of novel diagnostics, screening and safety testing, and curative treatments. For more information, visit Article content Article content Article content Article content
